Datametrex - CEO, Marshall Gunter.
CEO, Marshall Gunter.
Source: LinkedIn.
  • Datametrex AI (DM) has received a $100,000 purchase order from an insurance company
  • The order is for  the Operating System Calibration Management and Monitoring System(SysMind), which is server automation operations solution software
  • SysMind offers distinctive monitoring, calibration, and predictive analytics to eliminate risk and human error
  • Datametrex AI (DM) is a technology-focused company
  • Datametrex AI Ltd. (DM) is up 5.56 per cent on the day, trading at C$0.095 at 11:15 am ET

Datametrex AI (DM) has received a $100,000 purchase order from an insurance company.

The order is for the Operating System Calibration Management and Monitoring System(SysMind), which is server automation operations solution software.

MCV comes with fast mobile charging technology with a speed of over 45kwh with emergency charging and 24/7 on-demand EV services.

Marshall Gunter, CEO of Datametrex AI, commented on the order.

“The company is thrilled to see the expansion of the work with a Financial Group with the second P.O. from them. Management is continuously focusing on the land and expand strategy by strengthening client relationships. We are pleased with the results so far and look forward to continued contracts with our valued clients,”

Datametrex AI Limited is a technology-focused company using artificial intelligence (AI) to create progressive solutions for the cyber security, telehealth, and electric vehicle (EV) verticals.

Datametrex AI Ltd. (DM) is up 5.56 per cent on the day, trading at C$0.095 at 11:15 am ET.


More From The Market Online

Liberty Defense expands its international customer base

Liberty Defense Holdings (TSXV:SCAN), a provider of artificial intelligence technologies, expands its international customer base.

Unsung profits: Three microcap stocks with a strong case for value

A key factor behind picking winning microcap value stocks is identifying dislocations between company performance and market perception.

Theralase advances cancer research after private placement

Theralase Technologies (TSXV:TLT) closes a non-brokered private placement offering of 4.1 million shares for gross proceeds of C$750,200.